ELISA Kit for Complement Component 4a (C4a)

Format

48T, 96T, 96T×5, 96T×10, 96T×100

Detection range

0.312-20ng/mL

Application

Enzyme-linked immunosorbent assay for Antigen Detection.

Organism species

Homo sapiens (Human)

Sensitivity

The minimum detectable dose of this kit is typically less than 0.152ng/mL

Sample type

Serum, plasma and other biological fluids

Assay length

3h

Method

Double-antibody Sandwich

Test principle

The test principle applied in this kit is Sandwich enzyme immunoassay. The microtiter plate provided in this kit has been pre-coated with an antibody specific to Complement Component 4a (C4a). Standards or samples are then added to the appropriate microtiter plate wells with a biotin-conjugated antibody specific to Complement Component 4a (C4a). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain Complement Component 4a (C4a), biotin-conjugated antibody and enzyme-conjugated Avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Complement Component 4a (C4a) in the samples is then determined by comparing the O.D. of the samples to the standard curve.

Alternative Names

C4a anaphylatoxin

Item Name

Complement Component 4a

Research Area

Immune molecule;Endocrinology;

Reference

Circulation levels of acute phase proteins in patients with Takayasu arteritis;Identification of Altered Plasma Proteins by Proteomic Study in Valvular Heart Diseases and the Potential Clinical Significance;Higher Serum Angiotensinogen Is an Indicator of IgA Vasculitis with Nephritis Revealed by Comparative Proteomes Analysis;Plasma Protein Biomarkers of Hepatocellular Carcinoma in HCV-Infected Alcoholic Patients with Cirrhosis;Quantitative analysis of hydroxyapatite-binding plasma proteins in genotyped individuals with late-stage age-related macular degeneration;